Pantoprazol Pharmline (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Pharmline, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults.

GNH USA supplies Pantoprazol Pharmline as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Pharmline belongs to the proton pump inhibitor class and is indicated for conditions involving excess gastric acid secretion. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis. - Erosive duodenal ulcer: accelerates ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with gastrin‑producing tumours.

Adverse reactions to Pantoprazol Pharmline are generally mild to moderate and vary in frequency.

Common Side Effects: - Headache: mild, transient headache reported in clinical studies. - Diarrhoea: loose stools occurring in a minority of patients. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: persistent diarrhoea indicating possible colonic overgrowth. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Fracture risk: potential decrease in bone mineral density with long‑term use. - Liver enzyme elevation: increased ALT/AST indicating hepatic stress.

When prescribing Pantoprazol Pharmline, clinicians should consider several safety aspects. - Assess renal function: dose adjustment may be required in severe impairment. - Monitor electrolytes: prolonged therapy can affect magnesium and potassium levels. - Evaluate bone health: long‑term use may increase fracture risk, especially in elderly patients. - Review concomitant medications: potential for drug‑drug interactions, particularly with antiplatelet agents. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Pantoprazol Pharmline can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect may increase cardiovascular event risk. - Atazanavir: decreased absorption leading to loss of antiviral efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring more frequent monitoring. - Methotrexate: reduced renal clearance may raise serum levels. - Digoxin: slight increase in serum concentration, monitor for toxicity.